What it's for (Indications)
- Hormone Replacement Therapy (HRT) with estradiol valerate and dydrogesterone, such as Femoston Conti, is specifically indicated for the alleviation of symptoms of estrogen deficiency in postmenopausal women who have an intact uterus.
- This includes the management of moderate to severe vasomotor symptoms like hot flashes and night sweats, which are common manifestations of menopause and can significantly impair quality of life.
- Furthermore, this continuous combined HRT regimen is indicated for the prevention of osteoporosis in postmenopausal women who are at high risk of future fractures and who are intolerant of, or have contraindications to, other non-estrogen medicinal products approved for osteoporosis prevention.
- It is important that treatment initiation considers a thorough risk-benefit assessment and is generally recommended for women at least 12 months post-menopause to ensure amenorrhoea before commencing a continuous combined regimen.
- The primary goal is symptomatic relief and disease prevention when appropriate, always aiming for the lowest effective dose for the shortest possible duration.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for estradiol valerate + dydrogesterone (e.g., Femoston Conti) typically involves the oral administration of one tablet daily, continuously, without interruption. This formulation provides a fixed combination of estrogen (estradiol valerate) and progestogen (dydrogesterone) in a continuous regimen, designed to prevent monthly withdrawal bleeding in most postmenopausal women, which is often a desirable outcome for patients. Specific strengths, such as 1 mg estradiol valerate combined with 5 mg dydrogesterone, or 0.5 mg estradiol valerate with 2.5 mg dydrogesterone, are available to allow for dose titration based on individual needs. The selection of the starting dose and subsequent adjustments should be individualized based on the patient's symptoms, medical history, and response to treatment, always aiming for the lowest effective dose for the shortest possible duration consistent with treatment goals. Regular re-evaluation of the need for continued therapy, typically annually, is paramount to ensure the ongoing benefit-risk profile remains favorable. |
Safety & Warnings
Common Side Effects
- Patients undergoing treatment with estradiol valerate and dydrogesterone may experience a range of side effects, varying in severity and frequency.
- Common adverse reactions often include breast pain or tenderness, headache, abdominal pain, nausea, and vaginal bleeding or spotting, particularly during the initial months of treatment as the body adjusts to the hormonal changes.
- Other frequently reported effects include weight fluctuations, fluid retention, dizziness, and changes in libido.
- Less common but more serious side effects necessitate immediate medical attention and include an increased risk of venous thromboembolism (VTE), arterial thromboembolic events such as myocardial infarction and stroke, breast cancer, endometrial hyperplasia, and potentially ovarian cancer.
- Gallbladder disease, liver dysfunction, exacerbation of pre-existing conditions like endometriosis, uterine fibroids, porphyria, and angioedema are also potential adverse events.
- Any persistent or severe symptoms, particularly those indicative of thromboembolism or liver dysfunction, should prompt a medical review and potential cessation of therapy.
Serious Warnings
- Black Box Warning: **WARNING: CARDIOVASCULAR DISORDERS, MALIGNANT NEOPLASMS, AND PROBABLE DEMENTIA** **Cardiovascular Disorders:** Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. The Women's Health Initiative (WHI) study reported an increased risk of myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism in postmenopausal women receiving daily combined oral estrogen plus progestin therapy. Specifically, an increased risk of stroke and deep vein thrombosis was observed in women receiving estrogen-alone therapy. These risks should be carefully weighed against the potential benefits of symptom relief, and the lowest effective dose for the shortest duration consistent with treatment goals should be used, with regular reassessment of the need for continued therapy. **Malignant Neoplasms:** The WHI study found an increased risk of invasive breast cancer with combined estrogen plus progestin therapy. Estrogen-alone therapy has been associated with an increased risk of endometrial cancer in women with an intact uterus; however, the addition of a progestin like dydrogesterone significantly reduces this risk. An increased risk of ovarian cancer has been suggested in some epidemiological studies with long-term use of estrogen-alone and combined estrogen plus progestin HRT, although the absolute risk is small and causality remains under investigation. **Probable Dementia:** The WHI Memory Study (WHIMS) reported an increased risk of probable dementia in postmenopausal women 65 years of age or older receiving combined estrogen plus progestin therapy or estrogen-alone therapy compared to placebo. It is not known whether this finding applies to younger postmenopausal women, and HRT is not indicated for the prevention of dementia. Therefore, a thorough individual risk-benefit assessment, considering cardiovascular risk factors, personal and family cancer history, and cognitive function, must precede and regularly accompany the use of estradiol valerate and dydrogesterone.
- Prior to initiating or reinstituting Hormone Replacement Therapy (HRT) with estradiol valerate + dydrogesterone, a comprehensive medical history, including family history, and a thorough physical examination (encompassing blood pressure, breast, and pelvic examinations) must be performed and repeated periodically.
- Treatment should only be initiated after careful consideration of the individual's risk factors and benefits.
- HRT is associated with an increased risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, especially during the first year of use.
- The risk of stroke and myocardial infarction is also elevated, particularly in older women or those with pre-existing cardiovascular risk factors.
- An increased risk of breast cancer has been observed with combined estrogen-progestogen therapy, becoming apparent after a few years of use.
- While continuous combined HRT reduces the risk of endometrial hyperplasia and cancer compared to unopposed estrogen, all women with an intact uterus should receive progestogen.
- Caution is advised in patients with hypertension, diabetes mellitus, hypertriglyceridemia, liver impairment, migraine, cholelithiasis, systemic lupus erythematosus (SLE), epilepsy, asthma, otosclerosis, porphyria, endometriosis, and uterine fibroids, as HRT may exacerbate these conditions.
- Treatment must be discontinued immediately if symptoms of VTE, stroke, myocardial infarction, a significant increase in blood pressure, new-onset migraine-type headaches, jaundice, or severe liver dysfunction occur.
- The lowest effective dose for the shortest possible duration should always be sought.
How it Works (Mechanism of Action)
Estradiol valerate and dydrogesterone combine to provide effective hormone replacement therapy. Estradiol valerate is a prodrug that is rapidly hydrolyzed to estradiol, the primary and most potent endogenous estrogen in humans. Estradiol acts by binding to specific estrogen receptors (ERα and ERβ) located in the cytoplasm and nucleus of target cells throughout the body, including the reproductive organs, bone, brain, and cardiovascular system. This binding initiates a cascade of genomic and non-genomic effects, leading to the regulation of gene expression and cellular function. In postmenopausal women, estradiol replenishes declining endogenous estrogen levels, effectively alleviating menopausal symptoms such as vasomotor instability (hot flashes, night sweats), vaginal atrophy, and mood disturbances. Furthermore, estrogen has a well-established role in maintaining bone mineral density, thereby contributing to the prevention of osteoporosis. Dydrogesterone is a synthetic progestogen with a chemical structure similar to natural progesterone. Its primary mechanism of action involves binding to progesterone receptors in target tissues, particularly the endometrium. When administered in combination with estrogen in women with an intact uterus, dydrogesterone counteracts the proliferative effects of unopposed estrogen on the endometrium, thereby protecting against the development of endometrial hyperplasia and endometrial carcinoma. Unlike some other progestogens, dydrogesterone exhibits a high selectivity for progesterone receptors, with minimal androgenic, estrogenic, glucocorticoid, or mineralocorticoid activity, contributing to its favorable tolerability profile in many patients.
Commercial Brands (Alternatives)
No other brands found for this formula.